Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist.

[1]  J. Rosenstock,et al.  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. , 2021, The New England journal of medicine.

[2]  J. Rosenstock,et al.  Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial , 2021, The Lancet.

[3]  K. Gadde,et al.  Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study , 2021, Diabetes Care.

[4]  A. Evers,et al.  Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography , 2021, Diabetes.

[5]  A. Feuchtinger,et al.  The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling , 2021, Cell metabolism.

[6]  M. Samtani,et al.  Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose‐ranging study , 2021, Clinical obesity.

[7]  C. Mendivil,et al.  Diabetes and Bone Fragility , 2020, Diabetes Therapy.

[8]  M. Nauck,et al.  GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art , 2020, Molecular metabolism.

[9]  G. Antoni,et al.  Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes , 2020, Scientific Reports.

[10]  T. Kirchner,et al.  Amino acids are sensitive glucagon receptor‐specific biomarkers for glucagon‐like peptide‐1 receptor/glucagon receptor dual agonists , 2020, Diabetes, obesity & metabolism.

[11]  J. Holst,et al.  Dose‐dependent efficacy of the glucose‐dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3‐30)NH2 on GIP actions in humans , 2020, Diabetes, obesity & metabolism.

[12]  G. Antoni,et al.  Automated GMP-Compliant Production of [68Ga]Ga-DO3A-Tuna-2 for PET Microdosing Studies of the Glucagon Receptor in Humans , 2020, Pharmaceuticals.

[13]  J. Holst,et al.  Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes , 2020, Journal of the Endocrine Society.

[14]  A. Evers,et al.  Multiparameter Peptide Optimization toward Stable Triple Agonists for the Treatment of Diabetes and Obesity , 2020, Advanced Therapeutics.

[15]  M. Nauck,et al.  The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists , 2020, Diabetes, obesity & metabolism.

[16]  T. Okanoue,et al.  Current and new pharmacotherapy options for non-alcoholic steatohepatitis , 2020, Expert opinion on pharmacotherapy.

[17]  M. Coghlan,et al.  How May GIP Enhance the Therapeutic Efficacy of GLP-1? , 2020, Trends in Endocrinology & Metabolism.

[18]  M. Camilleri,et al.  Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. , 2020, Advances in experimental medicine and biology.

[19]  Gina M. Butrico,et al.  Glucagon stimulates gluconeogenesis by InsP3R-I mediated hepatic lipolysis , 2020, Nature.

[20]  D. V. van Raalte,et al.  Cardiovascular effects of GLP-1 receptor agonists: from mechanistic studies in humans to clinical outcomes. , 2019, Cardiovascular research.

[21]  T. Müller,et al.  Glucagon Regulation of Energy Expenditure , 2019, International journal of molecular sciences.

[22]  G. Antoni,et al.  Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates , 2019, Scientific Reports.

[23]  H. Grill,et al.  Glucagon-like peptide 1 (GLP-1) , 2019, Molecular metabolism.

[24]  J. Holst,et al.  A Pilot Study Showing Acute Inhibitory Effect of GLP‐1 on the Bone Resorption Marker CTX in Humans , 2019, JBMR plus.

[25]  J. Holst,et al.  Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. , 2019, The Journal of clinical endocrinology and metabolism.

[26]  G. Hessler,et al.  Peptide Optimization at the Drug Discovery-Development Interface: Tailoring of Physicochemical Properties Toward Specific Formulation Requirements. , 2019, Journal of pharmaceutical sciences.

[27]  A. Evers,et al.  First-in-class positron emission tomography tracer for the glucagon receptor , 2019, EJNMMI Research.

[28]  M. Tschöp,et al.  Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism , 2018, Molecular metabolism.

[29]  G. Arnold,et al.  Amino acid disorders. , 2018, Annals of translational medicine.

[30]  T. Vilsbøll,et al.  Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD , 2018, Front. Endocrinol..

[31]  M. Tschöp,et al.  Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases , 2018, Nature Reviews Endocrinology.

[32]  R. Gimeno,et al.  LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept , 2018, Molecular metabolism.

[33]  Y. Hijazi,et al.  A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials , 2018, Diabetes, obesity & metabolism.

[34]  L. Jermutus,et al.  MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study , 2018, British journal of clinical pharmacology.

[35]  A. Evers,et al.  Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys. , 2018, Endocrinology.

[36]  A. Evers,et al.  Running on mixed fuel‐dual agonistic approach of GLP‐1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non‐human primates , 2018, Diabetes, obesity & metabolism.

[37]  Søren L Pedersen,et al.  Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives. , 2018, ACS medicinal chemistry letters.

[38]  A. Evers,et al.  Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations. , 2018, Journal of medicinal chemistry.

[39]  M. Stumvoll,et al.  MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study , 2018, The Lancet.

[40]  J. Holst,et al.  Hemodynamic Effects of Glucagon: A Literature Review , 2018, The Journal of clinical endocrinology and metabolism.

[41]  D. Drucker.  Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. , 2018, Cell metabolism.

[42]  E. Wolf,et al.  Animal models of obesity and diabetes mellitus , 2018, Nature Reviews Endocrinology.

[43]  M. Gillum,et al.  Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis , 2018, World journal of gastroenterology.

[44]  R. DiMarchi,et al.  Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG7697 in people with type 2 diabetes mellitus , 2017, Diabetes, obesity & metabolism.

[45]  R. DiMarchi,et al.  Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG7697 after single subcutaneous administration in healthy subjects , 2017, Diabetes, obesity & metabolism.

[46]  M. Tschöp,et al.  The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. , 2017, Cell metabolism.

[47]  D. Dardevet,et al.  Glucagon's effect on liver protein metabolism in vivo. , 2017, American journal of physiology. Endocrinology and metabolism.

[48]  A. Evers,et al.  Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. , 2017, Journal of medicinal chemistry.

[49]  M. Tschöp,et al.  The New Biology and Pharmacology of Glucagon. , 2017, Physiological reviews.

[50]  J. Holst,et al.  Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. , 2017, Bone.

[51]  A. Murphy,et al.  Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice , 2017, Proceedings of the National Academy of Sciences.

[52]  L. Blonde,et al.  Differential effects of glucagon-like peptide-1 receptor agonists on heart rate , 2017, Cardiovascular Diabetology.

[53]  C. Meyer,et al.  Insulin does not stimulate muscle protein synthesis during increased plasma branched-chain amino acids alone but still decreases whole body proteolysis in humans. , 2016, American journal of physiology. Endocrinology and metabolism.

[54]  M. Bednarek,et al.  Robust anti‐obesity and metabolic effects of a dual GLP‐1/glucagon receptor peptide agonist in rodents and non‐human primates , 2016, Diabetes, obesity & metabolism.

[55]  M. Tschöp,et al.  Reappraisal of GIP Pharmacology for Metabolic Diseases. , 2016, Trends in molecular medicine.

[56]  J. Mattison,et al.  Obesity and Aging in Humans and Nonhuman Primates: A Mini-Review , 2016, Gerontology.

[57]  J. Mayer,et al.  Pursuit of a perfect insulin , 2016, Nature Reviews Drug Discovery.

[58]  J. Holst,et al.  Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors , 2015, British journal of pharmacology.

[59]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[60]  O. Fiehn,et al.  Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass. , 2015, Cell reports.

[61]  Lawrence A Leiter,et al.  Minimizing Hypoglycemia in Diabetes , 2015, Diabetes Care.

[62]  A. Murphy,et al.  Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys. , 2015, Endocrinology.

[63]  R. Becker,et al.  Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects , 2015, Diabetes/metabolism research and reviews.

[64]  R. Seeley,et al.  A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents , 2014, Nature Medicine.

[65]  M. Christensen,et al.  Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. , 2014, The Journal of clinical endocrinology and metabolism.

[66]  J. Holst,et al.  Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. , 2014, The Journal of clinical endocrinology and metabolism.

[67]  M. Horowitz,et al.  Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia , 2014, Diabetes.

[68]  D. Owens,et al.  Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. , 2013, Diabetes & metabolism.

[69]  D. Drucker,et al.  Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.

[70]  N. Irwin,et al.  A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1, and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice* , 2013, The Journal of Biological Chemistry.

[71]  R. Becker,et al.  Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia , 2013, Regulatory Peptides.

[72]  O. Korsgren,et al.  In Vivo Imaging of the Glucagonlike Peptide 1 Receptor in the Pancreas with 68Ga-Labeled DO3A-Exendin-4 , 2013, The Journal of Nuclear Medicine.

[73]  P. Flatt,et al.  A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. , 2013, Biochemical pharmacology.

[74]  M. Horowitz,et al.  Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones , 2013, Diabetes Care.

[75]  P. Flatt,et al.  A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice , 2013, Diabetologia.

[76]  Margaret S. Wu,et al.  Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist , 2012, PloS one.

[77]  J. Holst,et al.  Glucose-Dependent Insulinotropic Polypeptide , 2011, Diabetes.

[78]  J. Holst,et al.  Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans , 2011, Diabetes.

[79]  R. Gomis,et al.  Development and Functional Characterization of Insulin-releasing Human Pancreatic Beta Cell Lines Produced by Electrofusion* , 2011, The Journal of Biological Chemistry.

[80]  R. Bottino,et al.  Hemoglobin A1C Percentage in Nonhuman Primates: A Useful Tool to Monitor Diabetes before and after Porcine Pancreatic Islet Xenotransplantation , 2011, Journal of transplantation.

[81]  R. DiMarchi,et al.  Optimization of the Native Glucagon Sequence for Medicinal Purposes , 2010, Journal of diabetes science and technology.

[82]  L. B. Knudsen.  Liraglutide: the therapeutic promise from animal models , 2010, International journal of clinical practice. Supplement.

[83]  P. J. Larsen,et al.  Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. , 2010, The Journal of endocrinology.

[84]  S. Woods,et al.  A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. , 2009, Nature chemical biology.

[85]  P. Nilsson,et al.  Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. , 2009, The Journal of clinical endocrinology and metabolism.

[86]  W. Bollag,et al.  Impact of Glucose‐Dependent Insulinotropic Peptide on Age‐Induced Bone Loss , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[87]  L. B. Knudsen,et al.  Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not , 2007, Diabetes.

[88]  D. Drucker,et al.  Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. , 2005, Endocrinology.

[89]  C. Deacon.  Circulation and Degradation of GIP and GLP-1 , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[90]  J. Holst,et al.  GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. , 1999, The American journal of physiology.

[91]  D. King,et al.  A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. , 1990, International journal of peptide and protein research.

[92]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[93]  O. Owen,et al.  Effects of glucagon on plasma amino acids. , 1984, The Journal of clinical investigation.

[94]  J. Holst,et al.  Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia , 2018, The Journal of clinical endocrinology and metabolism.

[95]  C. Mantzoros,et al.  Pharmacotherapy of type 2 diabetes: An update. , 2018, Metabolism: clinical and experimental.

[96]  O. Eriksson,et al.  Fully automated GMP production of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for clinical use. , 2017, American journal of nuclear medicine and molecular imaging.

[97]  M. Erion,et al.  Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents , 2012, Biopolymers.